NO20021450L - Cykliske aminforbindelser som CCR5-antagonister - Google Patents
Cykliske aminforbindelser som CCR5-antagonisterInfo
- Publication number
- NO20021450L NO20021450L NO20021450A NO20021450A NO20021450L NO 20021450 L NO20021450 L NO 20021450L NO 20021450 A NO20021450 A NO 20021450A NO 20021450 A NO20021450 A NO 20021450A NO 20021450 L NO20021450 L NO 20021450L
- Authority
- NO
- Norway
- Prior art keywords
- amine compounds
- cyclic amine
- ccr5 antagonists
- ccr5
- antagonists
- Prior art date
Links
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title 1
- -1 Cyclic amine compounds Chemical class 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28208899 | 1999-10-01 | ||
| JP2000046749 | 2000-02-18 | ||
| PCT/JP2000/006755 WO2001025200A1 (en) | 1999-10-01 | 2000-09-29 | Cyclic amine compounds as ccr5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20021450D0 NO20021450D0 (no) | 2002-03-22 |
| NO20021450L true NO20021450L (no) | 2002-06-03 |
Family
ID=26554466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021450A NO20021450L (no) | 1999-10-01 | 2002-03-22 | Cykliske aminforbindelser som CCR5-antagonister |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6562978B1 (de) |
| EP (2) | EP1220842B1 (de) |
| JP (2) | JP3814136B2 (de) |
| KR (1) | KR20020060190A (de) |
| CN (1) | CN1390201A (de) |
| AR (1) | AR025884A1 (de) |
| AT (1) | ATE400555T1 (de) |
| AU (1) | AU7448700A (de) |
| BR (1) | BRPI0014428B8 (de) |
| CA (2) | CA2608807A1 (de) |
| CO (1) | CO5380013A1 (de) |
| CY (1) | CY1108403T1 (de) |
| DE (1) | DE60039446D1 (de) |
| DK (1) | DK1220842T3 (de) |
| ES (1) | ES2310173T3 (de) |
| HU (1) | HUP0300138A3 (de) |
| NO (1) | NO20021450L (de) |
| PE (1) | PE20010628A1 (de) |
| PL (1) | PL203984B1 (de) |
| PT (1) | PT1220842E (de) |
| WO (1) | WO2001025200A1 (de) |
| ZA (1) | ZA200202593B (de) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| AU2001288110A1 (en) * | 2000-09-27 | 2002-04-08 | Takeda Chemical Industries Ltd. | Spiro compounds |
| SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| CA2432527A1 (en) * | 2000-12-22 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Medicinal compositions for oral use |
| KR20030069218A (ko) * | 2001-01-18 | 2003-08-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 벤질피페리딘 화합물의 제조 방법 |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| WO2002088089A1 (en) * | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions |
| US20050154016A1 (en) * | 2002-04-19 | 2005-07-14 | Katsunori Takashima | Preventives for hiv infection |
| CA2483253A1 (en) * | 2002-04-24 | 2003-11-06 | Takeda Pharmaceutical Company Limited | Use of compounds having ccr antagonism |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| AU2003266528A1 (en) * | 2002-09-20 | 2004-04-08 | Takeda Pharmaceutical Company Limited | Cyclic amine compound, process for producing the same, and use |
| EP1553098A1 (de) * | 2002-10-18 | 2005-07-13 | Ono Pharmaceutical Co., Ltd. | Verbindungen spiroheterocyclischer derivate und arzneimittel, die die verbindungen als wirkstoff enthalten |
| AU2003290323A1 (en) * | 2002-12-24 | 2004-07-22 | Biofocus Plc | Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| WO2005059107A2 (en) | 2003-12-11 | 2005-06-30 | Anormed Inc. | Chemokine receptor binding compounds |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| SE0403084D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Chemical process |
| WO2006067531A1 (en) * | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| BRPI0519288A2 (pt) | 2004-12-24 | 2009-01-06 | Astrazeneca Ab | compostos heterocÍclicos como antagonistas de ccr2b |
| WO2006130426A2 (en) * | 2005-05-27 | 2006-12-07 | Kemia, Inc. | Modulators of ccr-5 activity |
| AU2013200480B2 (en) * | 2006-02-28 | 2016-06-09 | Dart Neuroscience (Cayman) Ltd. | Therapeutic compounds |
| JP5503874B2 (ja) | 2006-02-28 | 2014-05-28 | ダート ニューロサイエンス （ケイマン） エルティーディー | 治療化合物 |
| BRPI0708337A2 (pt) | 2006-02-28 | 2011-05-24 | Helicon Therapeutics Inc | pipirazinas terapêutica como inibidores pde4 |
| US8247442B2 (en) * | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
| TW200815353A (en) * | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
| TW200812963A (en) * | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| WO2008073450A2 (en) * | 2006-12-12 | 2008-06-19 | Georgetown University | Benzamide compounds |
| GB0625523D0 (en) * | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
| US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| ES2663517T3 (es) | 2007-08-27 | 2018-04-13 | Dart Neuroscience (Cayman) Ltd | Compuestos terapéuticos de isoxazol |
| US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| WO2009045382A1 (en) | 2007-10-04 | 2009-04-09 | Merck & Co., Inc. | Substituted aryl sulfone derivatives as calcium channel blockers |
| US8772297B2 (en) * | 2010-02-17 | 2014-07-08 | Kyoto University | TGF-β signal transduction inhibitor |
| AR080375A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida |
| MX2012011415A (es) | 2010-04-02 | 2013-02-26 | Phivco 1 Llc | Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico. |
| CN101921224B (zh) * | 2010-05-21 | 2012-01-18 | 中国人民解放军军事医学科学院生物工程研究所 | 1-（3-氨基丙基）哌嗪-4-氨基酰胺类化合物及其制备方法与应用 |
| KR200453948Y1 (ko) * | 2011-02-28 | 2011-06-09 | 최문희 | 파마로드 |
| WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| CN103130709B (zh) * | 2011-11-22 | 2017-04-12 | 常州亚邦制药有限公司 | 具有抗hiv活性的3‑氨基丙酸哌啶酰胺类化合物，合成方法及用途 |
| KR101939710B1 (ko) | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| UY34993A (es) | 2012-08-28 | 2014-02-28 | Janssen R & D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| JP6419155B2 (ja) | 2013-04-03 | 2018-11-07 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用 |
| JO3583B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| HRP20181863T1 (hr) | 2013-05-17 | 2018-12-28 | Janssen Sciences Ireland Uc | Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| NO3024819T3 (de) | 2013-07-25 | 2018-07-21 | ||
| MX368158B (es) * | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| WO2015120178A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
| DK3102572T3 (en) | 2014-02-06 | 2019-02-04 | Janssen Sciences Ireland Uc | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
| US10752588B2 (en) | 2014-12-19 | 2020-08-25 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
| EP3233077B1 (de) | 2014-12-19 | 2026-05-06 | The Broad Institute, Inc. | Dopamin-d2-rezeptor-liganden |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
| WO2018236745A1 (en) | 2017-06-20 | 2018-12-27 | Carnot, Llc | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CARDIAC METABOLISM |
| JP2021515769A (ja) | 2018-03-14 | 2021-06-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合調節剤の投薬レジメン |
| US12286401B2 (en) | 2018-07-31 | 2025-04-29 | The Trustees Of The University Of Pennsylvania | Small molecules that sensitize HIV-1 infected cells to antibody dependent cellular cytotoxicity |
| EP4497474A3 (de) | 2018-10-17 | 2025-04-23 | Imbria Pharmaceuticals, Inc. | Verfahren zur behandlung von rheumatischen erkrankungen unter verwendung von trimetazidinbasierten verbindungen |
| US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| EP3976101A4 (de) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | Verfahren zur behandlung von fibrose unter verwendung von verbindungen zur förderung der glucoseoxidation |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| CN114478585A (zh) * | 2020-10-26 | 2022-05-13 | 上海青煜医药科技有限公司 | 含氮稠杂环类化合物及其制备方法和应用 |
| WO2022223007A1 (zh) * | 2021-04-23 | 2022-10-27 | 中国人民解放军军事科学院军事医学研究院 | 抗病毒多肽化合物 |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| WO2023107547A2 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Azetidine and spiroazetidine compounds and uses thereof |
| IL317570A (en) * | 2022-06-13 | 2025-02-01 | Alivexis Inc | Azacycloalkylcarbonyl cyclic amines and their use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203988A (en) | 1975-11-12 | 1980-05-20 | Merck & Co., Inc. | Pyridinyl ureas and pharmaceutical use |
| JPH0680054B2 (ja) | 1985-06-19 | 1994-10-12 | 吉富製薬株式会社 | ピペリジン誘導体 |
| JP3638950B2 (ja) * | 1993-04-05 | 2005-04-13 | マンカインド コーポレイション | 神経障害の治療用ｍ▲下２▼レセプターリガンド |
| CA2296314A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| EP1052992A1 (de) | 1998-02-02 | 2000-11-22 | Merck & Co., Inc. | Cyclische amine modulatoren der chemokinrezeptoren |
| KR20030069218A (ko) * | 2001-01-18 | 2003-08-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 벤질피페리딘 화합물의 제조 방법 |
-
2000
- 2000-09-28 AR ARP000105104A patent/AR025884A1/es not_active Application Discontinuation
- 2000-09-28 PE PE2000001025A patent/PE20010628A1/es not_active Application Discontinuation
- 2000-09-29 US US10/089,374 patent/US6562978B1/en not_active Expired - Lifetime
- 2000-09-29 JP JP2000302841A patent/JP3814136B2/ja not_active Expired - Lifetime
- 2000-09-29 AT AT00962967T patent/ATE400555T1/de active
- 2000-09-29 BR BRPI0014428A patent/BRPI0014428B8/pt not_active IP Right Cessation
- 2000-09-29 PL PL356034A patent/PL203984B1/pl unknown
- 2000-09-29 DE DE60039446T patent/DE60039446D1/de not_active Expired - Lifetime
- 2000-09-29 EP EP00962967A patent/EP1220842B1/de not_active Expired - Lifetime
- 2000-09-29 AU AU74487/00A patent/AU7448700A/en not_active Abandoned
- 2000-09-29 WO PCT/JP2000/006755 patent/WO2001025200A1/en not_active Ceased
- 2000-09-29 HU HU0300138A patent/HUP0300138A3/hu unknown
- 2000-09-29 KR KR1020027004238A patent/KR20020060190A/ko not_active Abandoned
- 2000-09-29 CO CO00074305A patent/CO5380013A1/es not_active Application Discontinuation
- 2000-09-29 EP EP07119933A patent/EP1886994A1/de not_active Withdrawn
- 2000-09-29 ES ES00962967T patent/ES2310173T3/es not_active Expired - Lifetime
- 2000-09-29 PT PT00962967T patent/PT1220842E/pt unknown
- 2000-09-29 CA CA002608807A patent/CA2608807A1/en not_active Abandoned
- 2000-09-29 CN CN00815683A patent/CN1390201A/zh active Pending
- 2000-09-29 DK DK00962967T patent/DK1220842T3/da active
- 2000-09-29 CA CA2385938A patent/CA2385938C/en not_active Expired - Lifetime
-
2002
- 2002-03-22 NO NO20021450A patent/NO20021450L/no not_active Application Discontinuation
- 2002-04-03 ZA ZA200202593A patent/ZA200202593B/en unknown
- 2002-06-20 JP JP2002180545A patent/JP2003048880A/ja not_active Withdrawn
- 2002-10-18 US US10/273,111 patent/US7348324B2/en not_active Expired - Lifetime
-
2008
- 2008-10-08 CY CY20081101116T patent/CY1108403T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20021450D0 (no) | Cykliske aminforbindelser som CCR5 antagonister | |
| DK1218359T3 (da) | Piperazinforbindelser som tachykininantagonister | |
| NO20015366L (no) | Piperazinderivater som er anvendbare som CCR5-antagonister | |
| NO20015365L (no) | Piperidinderivater som er anvendbare som CCR5-antagonister | |
| NO20040028L (no) | Substituerte anilinske piperidiner som MCH-selektive antagonister | |
| NO20035739L (no) | N-aroyl syklisk aminderivater som orexin reseptorantagonister | |
| NO20052739D0 (no) | CCR5-antagonister som medikamenter | |
| DK1309559T3 (da) | 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister | |
| ATE318259T1 (de) | Selektive neurokinin-antagonisten | |
| NO20023485L (no) | 1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister | |
| ATE258554T1 (de) | Bicyclische imidazo-3-yl-aminderivate | |
| DK1163239T3 (da) | Modificerede aminosyreamider som CGRP-antagonister | |
| NO20025640L (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptorantagonister | |
| NO20004261L (no) | 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin- reseptor antagonister | |
| NO20021566D0 (no) | Bisykliske imidazo-5-yl-aminderivater | |
| DK1440059T3 (da) | 3-azabicyclo(3.1.0)hexanderivater som opioidreceptorantagonister | |
| DK1305319T3 (da) | 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister | |
| NO20021251D0 (no) | Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister | |
| NO20044373L (no) | Azetidinderivater som CCR-3-reseptorantagonister | |
| NO20032215D0 (no) | Laktamforbindelse | |
| DK0964863T3 (da) | Oxazolidinoner som 5-HT2A-antagonister | |
| NO20040877L (no) | Cyklisk aminforbindelse. | |
| DK1444206T3 (da) | Substituerede benzo[b]azepin-2-on-forbindelser som analgetika | |
| ATE418542T1 (de) | Als ccr5-antagonisten verwendbare aryloxim- piperazine | |
| NO20002575D0 (no) | Substituerte oksimer som neurokininantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |